Van ECK Associates Corp Sells 323,647 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Van ECK Associates Corp lowered its stake in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 14.3% during the 4th quarter, Holdings Channel.com reports. The fund owned 1,942,442 shares of the company’s stock after selling 323,647 shares during the quarter. Van ECK Associates Corp’s holdings in Teva Pharmaceutical Industries were worth $20,279,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Desjardins Global Asset Management Inc. increased its position in shares of Teva Pharmaceutical Industries by 15.2% during the 4th quarter. Desjardins Global Asset Management Inc. now owns 8,123 shares of the company’s stock valued at $85,000 after purchasing an additional 1,070 shares during the last quarter. DekaBank Deutsche Girozentrale increased its position in shares of Teva Pharmaceutical Industries by 2.1% during the 4th quarter. DekaBank Deutsche Girozentrale now owns 67,996 shares of the company’s stock valued at $688,000 after purchasing an additional 1,375 shares during the last quarter. ClariVest Asset Management LLC increased its position in shares of Teva Pharmaceutical Industries by 0.4% during the 3rd quarter. ClariVest Asset Management LLC now owns 399,900 shares of the company’s stock valued at $4,079,000 after purchasing an additional 1,400 shares during the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS increased its position in shares of Teva Pharmaceutical Industries by 0.8% during the 3rd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 178,827 shares of the company’s stock valued at $1,824,000 after purchasing an additional 1,500 shares during the last quarter. Finally, Transcend Capital Advisors LLC increased its position in shares of Teva Pharmaceutical Industries by 13.6% during the 4th quarter. Transcend Capital Advisors LLC now owns 12,543 shares of the company’s stock valued at $131,000 after purchasing an additional 1,500 shares during the last quarter. Institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Trading Down 0.5 %

Shares of TEVA opened at $14.03 on Wednesday. The company has a debt-to-equity ratio of 2.23, a current ratio of 1.02 and a quick ratio of 0.69. Teva Pharmaceutical Industries Limited has a 1 year low of $7.09 and a 1 year high of $14.47. The company has a 50 day simple moving average of $13.55 and a two-hundred day simple moving average of $11.50. The firm has a market cap of $15.73 billion, a P/E ratio of -29.85, a price-to-earnings-growth ratio of 1.69 and a beta of 1.05.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings data on Wednesday, January 31st. The company reported $0.98 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.73 by $0.25. Teva Pharmaceutical Industries had a negative net margin of 3.33% and a positive return on equity of 34.90%. The business had revenue of $4.46 billion during the quarter, compared to analyst estimates of $3.97 billion. On average, equities analysts expect that Teva Pharmaceutical Industries Limited will post 2.28 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the stock. Piper Sandler raised shares of Teva Pharmaceutical Industries from a “neutral” rating to an “overweight” rating and upped their price target for the company from $12.00 to $19.00 in a research report on Monday, February 12th. JPMorgan Chase & Co. raised shares of Teva Pharmaceutical Industries from an “underweight” rating to a “neutral” rating and set a $14.00 target price for the company in a report on Friday, March 8th. Barclays increased their target price on shares of Teva Pharmaceutical Industries from $15.00 to $17.00 and gave the stock an “overweight” rating in a report on Monday, February 5th. StockNews.com raised shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a report on Thursday, February 1st. Finally, The Goldman Sachs Group increased their target price on shares of Teva Pharmaceutical Industries from $10.00 to $11.00 and gave the stock a “neutral” rating in a report on Monday, February 5th. Three research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Teva Pharmaceutical Industries presently has a consensus rating of “Moderate Buy” and a consensus price target of $13.78.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, VP Eric Drape sold 9,815 shares of the stock in a transaction that occurred on Wednesday, February 28th. The shares were sold at an average price of $13.12, for a total transaction of $128,772.80. Following the completion of the sale, the vice president now directly owns 9,701 shares of the company’s stock, valued at approximately $127,277.12. The sale was disclosed in a legal filing with the SEC, which is available at this link. In other news, VP Eric Drape sold 9,815 shares of the stock in a transaction that occurred on Wednesday, February 28th. The stock was sold at an average price of $13.12, for a total transaction of $128,772.80. Following the completion of the transaction, the vice president now directly owns 9,701 shares in the company, valued at approximately $127,277.12. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Mark Sabag sold 100,000 shares of the stock in a transaction that occurred on Tuesday, March 5th. The shares were sold at an average price of $13.52, for a total value of $1,352,000.00. Following the transaction, the executive vice president now owns 382,590 shares of the company’s stock, valued at $5,172,616.80. The disclosure for this sale can be found here. Insiders sold a total of 390,738 shares of company stock valued at $5,132,766 in the last three months. 0.55% of the stock is currently owned by corporate insiders.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.